Cargando…

The GIP Receptor Displays Higher Basal Activity than the GLP-1 Receptor but Does Not Recruit GRK2 or Arrestin3 Effectively

BACKGROUND AND OBJECTIVES: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of insulin secretion, and their functional loss is an early characteristic of type 2 diabetes mellitus (T2DM). Pharmacological levels of GLP-1, but not GIP, can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Sabah, Suleiman, Al-Fulaij, Munya, Shaaban, Ghina, Ahmed, Hanadi A., Mann, Rosalind J., Donnelly, Dan, Bünemann, Moritz, Krasel, Cornelius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156404/ https://www.ncbi.nlm.nih.gov/pubmed/25191754 http://dx.doi.org/10.1371/journal.pone.0106890

Ejemplares similares

The Effect of Cell Surface Expression and Linker Sequence on the Recruitment of Arrestin to the GIP Receptor
por: Al-Sabah, Suleiman, et al.
Publicado: (2020)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Disentangling bias between G(q), GRK2, and arrestin3 recruitment to the M(3) muscarinic acetylcholine receptor
por: Flöser, Anja, et al.
Publicado: (2021)

Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor
por: Shaaban, Ghina, et al.
Publicado: (2016)

Correction: Al-Zamel, N., et al. A Dual GLP-1/GIP Receptor agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased agonist at the GLP-1 Receptor. Int. J. Mol. Sci. 2019, 20, 3532
por: Al-Zamel, Noura, et al.
Publicado: (2020)

Differential effects of glucose‐dependent insulinotropic polypeptide receptor/glucagon‐like peptide‐1 receptor heteromerization on cell signaling when expressed in HEK‐293 cells
por: Al‐Zaid, Bashaier, et al.
Publicado: (2022)

Identification of key phosphorylation sites in PTH1R that determine arrestin3 binding and fine-tune receptor signaling
por: Zindel, Diana, et al.
Publicado: (2016)

Dual single-scission event analysis of constitutive transferrin receptor (TfR) endocytosis and ligand-triggered β2-adrenergic receptor (β2AR) or Mu-opioid receptor (MOR) endocytosis
por: Lampe, Marko, et al.
Publicado: (2014)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Regulation of GIP and GLP1 Receptor Cell Surface Expression by N-Glycosylation and Receptor Heteromerization
por: Whitaker, Gina M., et al.
Publicado: (2012)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
por: Borner, Tito, et al.
Publicado: (2021)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2022)

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
por: Novikoff, Aaron, et al.
Publicado: (2021)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
por: Costa, Alessia, et al.
Publicado: (2021)

Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
por: Ying, Zhixiong, et al.
Publicado: (2023)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist
por: Erickson, Catherine E., et al.
Publicado: (2013)

Dissecting the roles of GRK2 and GRK3 in μ-opioid receptor internalization and β-arrestin2 recruitment using CRISPR/Cas9-edited HEK293 cells
por: Møller, Thor C., et al.
Publicado: (2020)

ACKR4 Recruits GRK3 Prior to β-Arrestins but Can Scavenge Chemokines in the Absence of β-Arrestins
por: Matti, Christoph, et al.
Publicado: (2020)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

CXCR7: a β-arrestin-biased receptor that potentiates cell migration and recruits β-arrestin2 exclusively through Gβγ subunits and GRK2
por: Nguyen, Huong Thi, et al.
Publicado: (2020)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

Double life: How GRK2 and β-arrestin signaling participate in diseases
por: Zhai, Ruxu, et al.
Publicado: (2022)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Ubiquitination of GRK2 Is Required for the β-Arrestin-Biased Signaling Pathway of Dopamine D2 Receptors to Activate ERK Kinases
por: Liu, Haiping, et al.
Publicado: (2023)

FRET-Based Detection of M(1) Muscarinic Acetylcholine Receptor Activation by Orthosteric and Allosteric Agonists
por: Markovic, Danijela, et al.
Publicado: (2012)

Galanin inhibits GLP‐1 and GIP secretion via the GAL(1) receptor in enteroendocrine L and K cells
por: Psichas, Arianna, et al.
Publicado: (2016)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice
por: Khan, Dawood, et al.
Publicado: (2022)

Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
por: Ma, Zijun, et al.
Publicado: (2023)

Role of Beta-Arrestin 2 Downstream of Dopamine Receptors in the Basal Ganglia
por: Del’Guidice, Thomas, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_bjc1pgcsbtbv69go3pic5e5566